This involves modeling continuous CTRED (not just high/low) against hippocampal APC, cognition, and incident dementia within a larger longitudinal cohort, and validating plasma-based markers (p-tau217/Aβ1–42) across different scanners and sites to ensure non-invasive applicability. Here, APC is linked to dementia.